NBIX Q3'26 Earnings: revenue estimate is 1.05B USD

What happened

Neurocrine Biosciences (NBIX) will report Q3'26 results on November 02 after the market closes, at 4:00 PM ET. The revenue estimate is 1.05 billion USD, and the earnings per share estimate is 1.93 USD.

Confirmed

Global impact / market context

Reported revenue has beaten estimates in each of the last four quarters, so investors will compare actual results with the 1.05 billion USD figure. A miss could reduce confidence in future sales growth, while a beat may support the stock.

Analyst inference

Earlier quarterly revenue grew steadily and came in above estimates, but earnings per share missed in two of the last four quarters. That mixed record means profit, not just sales, will likely shape how investors react to the update.

Analyst inference

What to watch

1. Watch whether reported Q3'26 revenue reaches the 1.05 billion USD estimate and whether earnings per share reaches 1.93 USD when results are released on November 02. Confirmed
2. The company could comment on sales trends for its medicines and on planned capital spending, meaning money for long-term investments, which would help investors judge future revenue growth. Proposed
3. Compare any reported profit per sale, which means margin, with prior quarters; weaker profitability despite higher revenue could weigh on the stock even if sales meet estimates. Analyst inference

Evidence

• Original source link unavailable